Business Wire

Vecima and Net-Com to Deploy Entra® DAA Remote MACPHY with Hanstholm Net in Denmark

22.5.2025 13:30:00 CEST | Business Wire | Press Release

Share

Vecima Networks Inc. (TSX: VCM) today announced that Net-Com is deploying Vecima’s Entra® SC-1D Access Node and Entra® Access Controller (“EAC”) solutions for Hanstholm Net, an internet service provider in Denmark.

Vecima's Entra SC-1D Remote MACPHY node, a key component of the Entra Distributed Access Architecture (“DAA”) product portfolio, equips cable operators to transition their networks toward greater efficiency and scalability. By moving MAC and PHY layer functions to the access edge, the SC-1D reduces core network load, lowers latency, and increases bandwidth availability, supporting efficient delivery of high-throughput services.

With enhanced DOCSIS® 3.1 support for Remote MACPHY nodes, the Entra SC-1D Access Node delivers fiber-comparable performance over existing HFC networks. It offers a cost-effective, easily deployable, and future-ready path to 10 Gigabit Internet access while preserving existing infrastructure investments.

Complementing the SC-1D, Vecima’s EAC serves as a centralized management platform that orchestrates the complex interactions between the core network and distributed access devices. The EAC ensures seamless integration and optimal performance of the DAA ecosystem, facilitating advanced features such as dynamic bandwidth allocation and network virtualization.

“Our transition to Distributed Access Architecture with Vecima’s Remote MACPHY solutions represents a strategic leap forward in both performance and scalability,” said Lars Røge Hamer, Chairman at Hanstholm Net. “Achieving a reduction in headend power consumption by around 60 percent, while unlocking the scalability needed for multigigabit services allows us to operate more efficiently and deliver next-generation connectivity without compromise.”

“Hanstholm Net’s adoption of Vecima’s technology through Net-Com, marks a strategic advancement in its network infrastructure to support high-performance broadband delivery”, said Gert K. Hansen, CTO at Net-Com. “This partnership represents an important step forward as Vecima’s reliable products and solid support align well with our plans to expand DOCSIS® services and support other operators as we continue to grow in Denmark.”

Equipped for multigigabit downstream capacity and fully licensed to support additional bandwidth without incremental costs, the Entra SC-1D Access Node offers operators a future-ready platform with simplified deployment and minimal operational overhead.

“As part of Vecima’s Remote MACPHY suite, the Entra SC-1D Access Node and Entra Access Controller together deliver significant performance gains and centralized orchestration, bridging the core network with distributed access devices through simplified, scalable control,” said Ryan Nicometo, Senior Vice President and General Manager, Vecima Video & Broadband Solutions. “We are excited that our partnership with Net-Com is bringing Vecima’s industry-leading access solutions to more operators in Europe. This reinforces our global market leadership in Remote MACPHY technologies.”

The Vecima DAA portfolio, recognized by the Dell’Oro Group for the fourth consecutive year as the global market share leader in R-MACPHY and Remote Optical Line Terminal solutions (“R-OLT”), is deployed by operators around the world. Vecima will showcase its industry-leading cable and fiber access solutions, including the SC-1D, at ANGA COM 2025.

Vecima Networks at ANGA COM 2025
June 3-5 in Cologne, Germany
Stand A20, Hall 8

About Hanstholm Net

Hanstholm Net is a local provider in Denmark, serving over 600+ cable TV customers, offering both television channels and high-speed internet. Their services are delivered via a hybrid network utilizing both coaxial cable and fiber optic infrastructure. Learn more at hanstholmnet.dk.

About Net-Com

Net-Com is a Danish distributor specializing in a broad range of network equipment to support both small-scale and enterprise-level network infrastructures. With expertise in telecommunications and networking solutions, Net-Com facilitates superior connectivity across Denmark. Learn more at net-com.dk.

About Vecima Networks

Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive. Learn more at vecima.com.

This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to, statements regarding Vecima's business strategies and objectives, and the anticipated benefits, performance, capabilities, availability or adoption of its products and services. Such statements reflect current expectations and assumptions about future events and are subject to risks and uncertainties. Vecima undertakes no obligation to update any forward-looking statements unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250522302302/en/

Contacts

Investor Relations : 250-881-1982, invest@vecima.com
Media Relations : bernadette.dunn@vecima.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye